Lansoprazole Delayed-Release Tablets Recalled Nationwide Due to Failed Dissolution Specifications
Dr. Reddy's Laboratories is recalling Lansoprazole 35 mg tablets nationwide because they failed dissolution specifications. The tablets may not release the active ingredient properly, reducing medication effectiveness.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall involves a manufacturing defect (failed dissolution specifications) affecting a prescription medication's ability to release and be absorbed properly. This represents a risk-of-harm product where patients may not receive adequate treatment for their medical condition, fitting the Score 3 (High) category per the severity rubric, particularly given the FDA Class II classification and lack of reported illnesses or injuries.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Lansoprazole Delayed-Release Orally Disintegrating Tablets, 35 mg, distributed nationwide in the United States. The recall affects 2,639 cartons with lot T2100515 and expiration date January 2023. The affected product is identified by NDC 43598-561-78 and blister barcode 4359856179.
The tablets failed to meet FDA dissolution specifications. When a tablet fails dissolution tests, the active ingredient may not be released and absorbed properly, which could result in reduced therapeutic effectiveness of the medication for treating acid reflux and related conditions.
Lansoprazole is a prescription proton pump inhibitor used to reduce stomach acid production and treat gastroesophageal reflux disease (GERD). Patients who have taken tablets from the recalled lot should contact their healthcare provider to discuss their treatment options and possible alternative medications.
Consumers should stop using the recalled tablets and contact their pharmacy or healthcare provider for guidance. The affected product should be returned to the pharmacy or disposed of according to local regulations. No illnesses or injuries have been reported in connection with this recall.
The recalled product
- Product
- LANSOPRAZOLE (LANSOPRAZOLE)
- Brand
- LANSOPRAZOLE
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug — Proton Pump Inhibitor
- Hazard
- dissolution-failure
- manufacturing-defect
- reduced-efficacy
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot T2100515
- Exp 01/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LANSOPRAZOLE
- HighLansoprazole tablets recalled nationwide due to failed dissolution specifications
FDA (Drugs) · 2022-08-03
- HighLansoprazole Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2022-05-11
- HighLansoprazole Capsules Recalled for Failed Dissolution in Stability Testing
FDA (Drugs) · 2022-04-06
- ModerateLansoprazole Delayed-Release Capsules Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-04-06
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27